{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T03:05:11Z","timestamp":1767236711464},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":950,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1093\/annonc\/mdx111","type":"journal-article","created":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T12:17:21Z","timestamp":1489407441000},"page":"1280-1287","source":"Crossref","is-referenced-by-count":42,"title":["Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant\/refractory advanced ovarian cancer"],"prefix":"10.1016","volume":"28","author":[{"given":"A.","family":"Poveda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"del Campo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Provansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.M.","family":"Guerra Al\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gonzalez-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kahatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fern\u00e1ndez Teruel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"Galmarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"P\u00e9rez de la Haza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Berton-Rigaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx111_bb0010","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-16-0172","article-title":"Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells","volume":"15","author":"Santamaria Nunez","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdx111_bb0015","series-title":"Proceedings of the 107th Annual Meeting of the American Association for Cancer Research","article-title":"Lurbinectedin reduces tumorassociated macrophages and the production of inflammatory cytokines, chemokines, and angiogenic factors in preclinical models","author":"Allavena","year":"2016"},{"key":"10.1093\/annonc\/mdx111_bb0020","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1158\/1078-0432.CCR-12-1513","article-title":"Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer","volume":"18","author":"Vidal","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1093\/annonc\/mdx111_bb0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx111_bb0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2009.27.8911","article-title":"Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"29","author":"Sehouli","year":"2011","journal-title":"J Clin Onocol"},{"issue":"4","key":"10.1093\/annonc\/mdx111_bb0035","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/annonc\/mdx010","article-title":"Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors","volume":"28","author":"McGee","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx111_bb0040","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1158\/1078-0432.CCR-13-1880","article-title":"First-in-human phase I study of lurbinectedin (PM01183) in patients with advanced solid tumors","volume":"20","author":"Elez","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx111_bb0045","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx111_bb0050","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx111_bb0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/IGC.0b013e3182049273","article-title":"Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube","volume":"21","author":"Griffiths","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdx111_bb0060","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx111_bb0065","doi-asserted-by":"crossref","unstructured":"Poveda AM, Selle F, Hilpert F et al. Weekly paclitaxel (PAC), pegylated liposomal doxorubicin (PLD) or topotecan (TOP) \u00b1 bevacizumab (BEV) in platinum (PT)-resistant recurrent ovarian cancer (OC): analysis by chemotherapy (CT) cohort in the GCIG AURELIA randomised phase III trial. Ann Oncol 2012; 23: ixe17 (abstract LBA26).","DOI":"10.1016\/S0923-7534(20)34331-3"},{"key":"10.1093\/annonc\/mdx111_bb0070","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2015.66.0787","article-title":"Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE)","volume":"34","author":"Kurzeder","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx111_bb0075","unstructured":"Fernandez-Teruel C, Del Campo JM, Berton-Rigaud D et al. Lurbinectedin (PM1183) efficacy in platinum resistant\/refractory ovarian cancer (PRROC) patients correlates with drug exposure using pharmacokinetic\/pharmacodynamic (PK\/PD) modelling. Int J Gynecol Cancer 2015;25:433."},{"key":"10.1093\/annonc\/mdx111_bb0080","doi-asserted-by":"crossref","unstructured":"Gaillard S, Ghamande SA, Pardo B et al. CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer. J Clin Oncol 2016;34.","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5597"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419324330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419324330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/6\/1280\/24169437\/mdx111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:26:00Z","timestamp":1624695960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419324330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0923753419324330"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx111","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}